Corinne Atton is an accomplished trial attorney with extensive experience representing life sciences- and technology-focused clients in complex and high-stakes intellectual property matters. Corinne's courtroom experience includes bench trials in U.S. district court; trials and motion practice before the Chancery Division (Patents Court) of the High Court of Justice of England and Wales; and appeals before the Court of Appeal (England and Wales). She also represents clients in inter partes review and post-grant review proceedings before the U.S. Patent Trial and Appeal Board.
Corinne also has experience with patent due diligence associated with high-profile acquisitions, and with intellectual property issues in commercial transactions. She focuses on pharmaceuticals, biologics, biotechnology, and medical devices. Corinne has worked on cases concerning DNA sequencing technologies, recombinant polypeptides, enzyme inhibitors, receptor agonists, iron chelators, anti-diabetic drugs, wakefulness-promoting agents, surgical mesh affixing systems, and laser hair removal systems.
Corinne edits, writes for, and manages Venable's BiologicsHQ microsite – a website that provides statistical analyses and timely commentary concerning U.S. patent proceedings relating to FDA-approved biologic drugs. She also regularly publishes and speaks on a wide variety of intellectual property topics and developments.
Corinne formerly practiced as a barrister in England and Wales, where she advised on high-value patent, trademark, and commercial litigation, and international arbitration matters.